2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat, largely due to its aggressive nature and tendency for late-stage diagnosis. However, recent advancements in cancer research offer glimmers of hope. Novel immunotherapies, targeted therapies, and combination treatments are being investigated to combat PDAC's resistance to conventional therapies. Additionally, genomic profiling has unveiled potential biomarkers for early detection and personalized treatment strategies. Innovative techniques like liquid biopsies hold promise for non-invasive monitoring of disease progression. Collaborative efforts between researchers, clinicians, and pharmaceutical companies are driving forward momentum in understanding PDAC's complex biology and developing more effective interventions. While significant challenges persist, the evolving landscape of cancer research offers optimism for improving outcomes in pancreatic ductal adenocarcinoma patients.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China